STELLAR PHARMACEUTICALS RECEIVES CE MARK FOR NEOVISC

Stellar Pharmaceuticals, a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, announced that its NeoVisc viscosupplementation therapy has received the CE Mark denoting conformity with European standards for safety and allowing for marketing in European Union countries. Stellar is in ongoing discussions with several interested parties to market and sell NeoVisc in the European Union.
Genetic Engineering News